NCT03754790
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
레지스트리 요약
- 진행 상태
- 완료 (COMPLETED)
- 질환/조건
- Hemophilia
- 시험 유형
- 중재 연구 (INTERVENTIONAL)
- 단계
- Phase 3
- 목적
- 치료
- 중재 유형
- 약물
- 개입·치료
- Fitusiran
- Lead Sponsor
- Genzyme, a Sanofi Company (산업계)
캐시 시각: 2026-10-01 04:05:12
요약
Primary Objective:
To characterize the long-term safety and tolerability of fitusiran
Secondary Objectives:
* To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of:
* Bleeding episodes
* Spontaneous bleeding episodes
* Joint bleeding episodes
* To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
To characterize the long-term safety and tolerability of fitusiran
Secondary Objectives:
* To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of:
* Bleeding episodes
* Spontaneous bleeding episodes
* Joint bleeding episodes
* To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
카카오 로그인 후 의뢰